Akumin — Q1 2023 Earnings Presentation
15 slides from Akumin's earnings presentation, May 11, 2023
Slide 1: 2023 First Quarter Results
Akumin Inc. 2023 First Quarter Results May 11, 2023 Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Q1 2023 Performance Highlights
Same Store Volumes trended positively across the platform: MRI: +4.0% PET/CT: +16.1% Oncology Patient Starts: +7.6% Q1 2023 Performance Revenue of $187.6M, up 0.7% vs. Q1 2022. Highlights Adjusted EBITDA1 of $33.1M, up 3.5% vs. Q1 2022. Adjusted EBITDA margin1 of 17.7%, up from 17.2% in
Slide 4: Operational Update
Operational Update Organic growth in Radiology: ‒ We experienced solid growth in MRI volumes as the impact of labor shortages moderated. ‒ PET/CT demonstrated impressive growth as a result of strong demand, particularly from our hospital partners. ‒ Organic volume growth largely offset reduced cap
Slide 5: Strategic Initiatives Underway
Strategic Initiatives Underway Driving same-store organic growth: ‒ Workforce productivity gains: Specific focus on improving scans or treatments per labor hour. ‒ Scheduling optimization: Improving the performance of call centers. ‒ Facility optimization: Re-opening certain facilities under renov
Slide 6: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities Service Lines (% of Revenue) 1 Radiology Procedure Mix Diversification of revenue (% of Revenue) between Radiology and Oncology divisions Akumin provides a full suite of radiology and oncology services with a focus on high-growth and high-value modalities Akumin
Slide 7: Diverse Payor Mix
Diverse Payor Mix TTM Q1’23 Payor Mix1 % of Revenue of the company’s overall ~95% revenue is derived from outpatient procedures 50% 50% of revenue is received of revenue is received via third party and via health systems government payors, and hospitals, of which and reimbursed at virtually all is f
Slide 8: Volume Trends
Volume Trends MRI, #K procedures PET/CT, #K procedures Oncology, #K patient starts 225.3 35.8 2.623 219.8 2.592 2.610 216.9 33.7 2.588 216.4 33.4 33.4 Q2'22 Q3'22 Q4'22 Q1'23 Q2'22 Q3'22 Q4'22 Q1'23 Q2'22 Q3'22 Q4'22 Q1'23 Same Store Volume Growth1,2, % growth YoY MRI (procedures) PET/CT (procedures
Slide 9: Segment Financial Performance
Segment Financial Performance Revenues ($ in M) Adjusted EBITDA1 and Margin (M) Oncology Radiology 50.0 22.0% 45.0 20.2% $192.1 $186.6 $184.6 $187.6 19.9% $186.3 19.6% 40.0 $30.9 $31.3 $31.5 $31.1 $30.2 17.2% 17.7% $38.2 $37.4 35.0 $36.5 $33.1 30.0 $32.0 $155.3 $160.9 $155.1 $153.6 $157.4 25.0 20.0
Slide 10: Segment Financial Performance
Segment Financial Performance Annual Pro Forma1 Revenue (M) Adj. EBITDA2 and Margin Pro Forma1 (M) Oncology Radiology Overall margin EBITDA $727 $750 $751 20.1% 19.3% $124 19.2% $125 $132 $146 $144 $145 $625 $627 $595 2021 2022 LTM Q1’23 2021 2022 LTM Q1’23 Source: Company financial reports. 1. Pro
Slide 11: Free Cash Flows (Q1 2023)
Free Cash Flows (Q1 2023) Free Cash Flow (FY 2023) (M) Increase Decrease AEBITDA Cash Interest Cash Minority Finance Working Cash Capex Other Quarterly Before MI Interest Lease & LT Capital 1 payments Nonrecurring 2 Cash Flow Debt Change Payments 1. Working Capital change excludes change in Interest
Slide 12: 2023 Guidance Reiterated
We expect 2023 results as follows: Revenue range $765M-$775M Adjusted EBITDA1 range $150M-$160M 2023 Guidance Total CAPEX spend of ~$55-$65M: Reiterated ‒ ~$20-$30M earmarked for growth capex for new customers and new sites ‒ Total capex to be funded with approx. 20% in cash and the balance fi
Slide 13: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation Adjusted EBITDA1 $155.0 for Growth Total Secured Debt $918.2 Akumin’s capital structure is comprised of a diverse set of capital providers Less: Cash 45.4 including traditional banks, bondholders and Stonepeak as debt and equity Net Secured Debt $872.8 stakehol
Slide 14: Thank you!
Thank you! Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 15: Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA Three-month period ended Trailing Twelve-month period ended 1 ($ in thousands) Mar 31, 2023 Mar 31, 2022 Mar 31, 2023 Mar 31, 2022 Net loss $ (29,190) $ (26,432) $ (154,346) $ (58,738) Interest expense 30,697 28,681 120,027 82,887 Income tax